Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist used extensively in glucose-regulation and body-composition protocols — a clinically studied, leading compound for incretin-pathway support. Typical Course: A full course runs 12 weeks. It begins with a 4-week loading phase at 2.5mg weekly, followed by a 4-week escalation phase at 5mg weekly once the starting dose is well tolerated, then a 4-week maintenance phase at 10mg weekly. Most customers notice initial effects around week 2, with results peaking around week 8. What to Expect: Appetite suppression, improved glucose regulation, body weight reduction and energy stabilisation. Key benefits include the dual GLP-1/GIP mechanism, an excellent tolerability profile, a well-studied compound profile and a consistent dose-escalation schedule. Considerations & Safety: Nausea is common in the first few weeks as the dose is increased; constipation and injection site reactions are also possible. Common side effects include nausea, vomiting, diarrhoea, constipation and decreased appetite. Seek medical attention immediately if you experience severe abdominal pain, persistent vomiting, an allergic reaction, or significant vision changes.